Sanjivani Paranteral Ltd does manufacturing and export of pharmaceutical productsBusiness Overview: Sanjivani Paranteral Ltd is a pharmaceutical company headquartered in Mumbai. It specializes in manufacturing and distribution of high-quality parenteral and oral solid products. It caters to major therapeutic areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported…
Sanjivani Paranteral Limited has released its investor presentation for the financial results for the quarter ended June 30, 2025. The company reported a revenue from operations of 17.89 Cr, an 8.9% increase year-on-year. Profit after Tax (PAT) stood at 1.73 Cr, up 1.0% from the previous year. EBITDA was 2.68...
Sanjivani Paranteral Limited has confirmed there is no deviation in the utilization of funds raised through the issuance of Convertible Warrants. The company raised ₹8.11 crore in January 2024 for its future expansion and growth. For the quarter ended June 30, 2025, the company reported that the funds, including the...
Sanjivani Paranteral Limited will host a conference call for investors and analysts on Tuesday, August 12, 2025, at 5:00 PM IST. The call aims to discuss the company's Q1 FY26 financial results. Key management, including the Chairman & MD, Director, and CFO, will participate, offering stakeholders direct insights into the...
Sanjivani Paranteral Limited has announced a board meeting to consider the financial results for the quarter and half-year. The company has submitted the confirmation certificate from its Registrar and Transfer Agent, MUFG Intime India Private Limited, affirming that all securities dematerialized during the quarter were processed and updated in the...
Sanjivani Paranteral Limited has announced a board meeting to approve the financial results for the quarter and half-year. The company received listing approval for 1,97,394 equity shares issued on a preferential basis to the promoter following the conversion of warrants. These shares have a face value of Rs. 10 each...
